Pharmaceutical and medical device companies increasingly collect gender identity data in clinical trials, patient support programs, and direct-to-patient (“DTP”) marketing. The aim is usually positive: increase representation, improve inclusion, or meet regulatory expectations. But mishandling this data carries real risks.
Under modern privacy frameworks, gender identity is treated as a form of sensitive data. Improper collection, storage, or use can trigger regulatory fines, lawsuits, reputational harm, and even investor scrutiny. For companies regulated by the Food and Drug Administration (“FDA”), those risks overlap with advertising, research integrity, and fraud/abuse oversight requirements. This means that what begins as a privacy misstep can quickly escalate into a full-blown business risk.
The Legal Regime: Data Privacy and Gender Identity
European Data Protection: The GDPR
The European Union’s General Data Protection Regulation (“GDPR”) applies to some activities originating within the United States, and U.S. life sciences companies need to pay attention to how it may affect their handling of gender identity data. The GDPR explicitly protects “special categories” of personal data, including health, sexual orientation, and biometric data. The EU generally legally recognizes that an individual can express a gender identity different from the one assigned to them at birth. Failure to accurately record a person’s chosen gender identity or not processing it where assigned sex at birth is not relevant would generally be seen as inconsistent with the GDPR principle of data accuracy.
U.S. State Laws: CCPA/CPRA and Beyond
A growing number of U.S. states have enacted privacy laws that may apply to gender identity data. In California, for example, the California Privacy Rights Act (“CPRA”) expanded the California Consumer Privacy Act (“CCPA”) to cover “sensitive personal information.” This includes traits such as sexual orientation and other markers tied to identity. Consumers can limit use of sensitive information to only what is “necessary” to deliver expected services.
The California attorney general has pursued California privacy law enforcement aggressively. Virginia, Colorado, and more than a dozen other states have adopted similarly comprehensive privacy laws. Depending on the jurisdictions they operate in, companies that mishandle identity data may risk scrutiny from multiple regulators simultaneously.
Data Mishandling and Discrimination Claims
As discussed, company policies for handling gender identity data should consider privacy law risks. However, they should also consider potential antidiscrimination law risks. Common pitfalls in the life sciences context include those below:
Scope Creep and Reuse
Clinical trial sponsors may initially collect gender identity for inclusion tracking but later reuse it for targeted marketing without consent. Vendors may repurpose identity data for unrelated analytics. Such actions are increasingly framed not as privacy errors but as profiling and discrimination.
Tokenism in Clinical Research
Claiming that a clinical trial is inclusive of transgender people without conducting meaningful subgroup analysis or including related endpoints can also lead to reputational and legal risk. Plaintiffs may argue that data was collected under false pretenses, creating exposure for deceptive or discriminatory practices.
Business Consequences of Mishandling Gender Identity Data
Regulatory Penalties
- GDPR fines: up to 4 percent of global turnover.
- CCPA/CPRA enforcement: fines up to $7,500 per violation.
- Corrective actions: regulators may require ongoing audits or data protection impact assessments (“DPIAs”).
Litigation Exposure
Privacy claims are increasingly bundled with discrimination and emotional distress allegations. Class actions can demand wide discovery, exposing vendor contracts and internal emails, and settlements often result simply to avoid reputational damage.
Reputational Fallout
Stories about companies and even government agencies allegedly mishandling or not adequately protecting gender identity data attract significant media coverage. Environmental, social, and governance (“ESG”) investors track governance issues related to marginalized groups closely, and activist campaigns can magnify even small missteps. Additionally, in the context of clinical research, subjects are supposed to be anonymized, and sponsors who turn over data to governmental authorities in response to a subpoena without mounting a significant challenge, or otherwise mounting a loud retreat, may discover that passive turnover of data constitutes a loss of trust and could result in reputational damage not only with targeted subjects, but also with patients as a whole.
Investor and Board Scrutiny
In M&A or private equity due diligence, weak gender identity data governance may be flagged as a material risk. Whistleblowers or employee advocates can raise red flags that disrupt deals or trigger post-closing disputes.
Best Practices for Life Sciences Companies
- Data Mapping and Classification: Treat gender identity data as high-risk data, similar to medical or biometric information.
- Purpose Limitation and Consent: Obtain explicit consent for collection and secondary use, especially in marketing.
- Access Controls: Compartmentalize data access and log usage. Consider anonymization or encryption.
- Vendor Oversight: Require contracts to limit use, enforce deletion in accordance with legal and policy requirements, and permit audits. Flow obligations down to subcontractors.
- Correction and Inclusion: Allow participants to update their gender identity data and offer options that enable them to indicate their gender identity accurately, including nonbinary or self-describe options.
- Transparency: Update privacy notices with clear language on why gender identity data is collected and how it is shared.
- Audits and Data Protection Impact Assessments (“DPIAs”): Conduct regular privacy impact assessments that specifically evaluate gender identity data risks.
- Training and Governance: Educate clinical, marketing, and IT teams on sensitive data risks. Establish a privacy governance committee with oversight over gender identity data.
Conclusion
For companies working in life sciences and adjacent sectors, mishandling gender identity data is more than a privacy problem and can escalate to become a trust problem. With regulators, plaintiffs’ attorneys, and investors watching closely, the business consequences are steep.
